HRP20161495T1 - Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) - Google Patents

Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) Download PDF

Info

Publication number
HRP20161495T1
HRP20161495T1 HRP20161495TT HRP20161495T HRP20161495T1 HR P20161495 T1 HRP20161495 T1 HR P20161495T1 HR P20161495T T HRP20161495T T HR P20161495TT HR P20161495 T HRP20161495 T HR P20161495T HR P20161495 T1 HRP20161495 T1 HR P20161495T1
Authority
HR
Croatia
Prior art keywords
bromo
diamine
pyrimidin
group
pyrazol
Prior art date
Application number
HRP20161495TT
Other languages
English (en)
Inventor
Juan CAMACHO GÓMEZ
Julio Castro Palomino Laria
Original Assignee
Palobiofarma S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma S.L. filed Critical Palobiofarma S.L.
Publication of HRP20161495T1 publication Critical patent/HRP20161495T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (22)

1. Spoj formule (I): [image] , naznačen time što: – R1 se bira iz skupine koju čine vodik, halogen, cikloalkil i alkil s tri ili četiri atoma ugljika, nerazgranat ili razgranat; – Y se bira iz skupine koju čine C-R2 i atom dušika; – R2 se bira iz skupine koju čine: (a) arilna ili heteroarilna skupina, koja može biti supstituirana s jednim ili više atoma halogena, ili s jednom ili više cikloalkilnih, hidroksi, (C1-C8) alkoksi, (C1-C8) alkiltio, amino, mono- ili dialkilamino, alkoksialkilnih, hidroksikarbonilnih i alkoksikarbonilnih skupina; (b) alkoksikarbonilna skupina formule (-CO(R7), gdje R7 predstavlja hidroksilnu skupinu ili skupinu [-N(R8)(R9)]; R8 i R9 se neovisno bira iz skupine koju čine atom vodika, cikloalkil i alkil s tri ili četiri atoma ugljika, nerazgranat ili razgranat i može biti supstituiran s halogenom ili arilnom ili heterocikličkom skupinom; ili R8 i R9, zajedno s atomom dušika na kojeg su vezani, tvore zasićeni pet- ili šesteročlani prsten, koji može sadržavati dodatni heteroatom, kojeg se bira iz skupine koju čine kisik i dušik, može biti supstituiran s (C1-C8) alkilnom skupinom; – R3 se bira iz skupine koju čine vodik, halogen, cikloalkilna skupina i (C1-C8) alkilna skupina, nerazgranata ili razgranata, koja može biti supstituirana s atomima halogena; ili R2 i R3, zajedno s atomima ugljika na kojeg su vezani, tvore šesteročlani arilni ili heteroarilni prsten, koji može biti supstituiran s jednim ili više atoma halogena, ili s jednom ili više skupina koje se bira između cikloalkila, hidroksi, (C1-C8) alkoksi, (C1-C8) alkiltio, amino, mono- ili dialkilamino, alkoksialkila, hidroksikarbonila i alkoksikarbonila; – X se bira iz skupine koju čine atom halogena i cijano skupina; – R4, R5 i R6 se neovisno bira iz skupine koju čine: (a) atom vodika; (b) alkilna, cikloalkilna ili cikloalkilalkilna skupina s najviše pet atoma ugljika, nerazgranata ili razgranata i može biti supstituirana s jednim ili više atoma halogena, metoksi skupina ili heteroarilnih skupina, gdje navedena heteroarilna skupina može biti supstituirana s atomima halogena ili (C1-C8) alkilnim skupinama; (c) alilna ili propargilna skupina, koja može biti supstituirana s jednim ili više atoma halogena ili s jednom ili više skupina koje se bira iz skupine koju čine cikloalkil, hidroksi, (C1-C8) alkoksi, (C1-C8) alkiltio, amino, mono- ili dialkilamino, alkoksialkil, hidroksikarbonil i alkoksikarbonil; i (d) tetrahidropiranilna skupina; ili R5 i R6 mogu, zajedno s atomom dušika na kojeg su vezani, tvoriti pirazolni ili triazolni prsten, koji može biti supstituiran s atomima halogena i njegove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R4 predstavlja atom vodika.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1, R3 i R5 predstavljaju atom vodika, X predstavlja atom broma, a Y predstavlja atom dušika.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što se R6 bira iz skupine koju čine alkil, cikloalkilalkil i alkilcikloalkil, koji može biti supstituiran s metoksi skupinom ili heteroarilom, koji pak može biti supstituiran s (C1-C8) alkilnom skupinom.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što se R6 bira iz skupine koju čine etil, propil, i ciklopropilmetil, od kojih sve mogu biti supstituirane s metoksi skupinom ili peteročlanom heteroarilnom skupinom, koja pak može biti supstituirana s jednom ili više metilnih skupina.
6. Spoj u skladu s patentnim zahtjevom 3, naznačen time što se R6 bira iz skupine koja se sastoji od skupine alil, propargil i tetrahidropiranil od kojih sve mogu biti supstituirane s alkilnom skupinom, nerazgranatom ili razgranatom, s najviše tri atoma ugljika.
7. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1, R3 i R5 predstavlja atom vodika, X predstavlja atom broma, Y predstavlja ostatak C-R2, a R2 predstavlja heteroarilnu skupinu, koja može biti supstituirana s atomima halogena.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što R2 se bira između piridina, kinolina, pirimidina ili pirazina, koji su mogu biti supstituirani s atomima halogena.
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine alkilna, cikloalkilalkilna i alkilcikloalkilna skupina, od kojih sve mogu biti supstituirane s metoksi skupinom ili s heteroarilnom skupinom, koja pak može biti supstituirana s (C1-C8) alkilnom skupinom.
10. Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine etil, propil, i ciklopropilmetil, koji može biti supstituiran s metoksi skupinom ili s peteročlanom heteroarilnom skupinom, koja može biti supstituirana s jednom ili više metilnih skupina.
11. Spoj u skladu s patentnim zahtjevom 8, naznačen time što se R6 bira iz skupine koju čine alilnu, propargilnu i tetrahidropiranilnu skupinu, koje mogu biti supstituirane s atomima halogena.
12. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1 i R5 predstavlja atom vodika, X predstavlja atom broma, Y predstavlja atom ugljika, a R2 i R3, zajedno s atomima ugljika na kojeg su vezani, tvore izborno supstituiranu arilnu ili heteroarilnu skupinu.
13. Spoj u skladu s patentnim zahtjevom 12, naznačen time što R2 i R3, zajedno s atomima ugljika na kojeg su vezani, tvore fenilni ili piridinski prsten, koji mogu biti supstituirani s atomima halogena.
14. Spoj u skladu s patentnim zahtjevom 13, naznačen time što se R6 bira iz skupine koju čine alkil, cikloalkilalkil i alkilcikloalkil, koji može biti supstituiran s metoksi skupinom ili heteroarilnom skupinom, koja pak može biti supstituirana s (C1-C8) alkilnom skupinom.
15. Spoj u skladu s patentnim zahtjevom 14, naznačen time što se R6 bira iz skupine koju čine etil, propil i ciklopropilmetil, može biti supstituiran s metoksi skupinom ili s peteročlanom heteroarilnom skupinom, koja može biti supstituirana s jednom ili više metilnih skupina.
16. Spoj u skladu s patentnim zahtjevom 13, naznačen time što se R6 bira iz skupine koju čine izborno supstituirani alil, propargil i tetrahidropiranil.
17. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1 i R5 predstavljaju atom vodika, X predstavlja atom broma, Y predstavlja ostatak CR2, R2 i R3, zajedno s atomima ugljika na koje su vezani, tvore fenilni ili piridinski prsten, a R6 se bira iz skupine koju čine etil, propil i ciklopropilmetil, koji može biti supstituiran s tiazolnim prstenom, koji može biti supstituiran s jednom ili više metilnih skupina.
18. Spoj u skladu s patentnim zahtjevom 2, naznačen time što R1, R3 i R5 predstavljaju atom vodika, X predstavlja atom broma, Y predstavlja atom dušika, a R6 se bira iz skupine koju čine etil, propil, propargil i ciklopropilmetil, koji može biti supstituiran s tiazolnim prstenom, koji pak može biti supstituiran s jednom ili više metilnih skupina.
19. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine: 5-brom-N4-(ciklopropilmetil)-2-(1H-indazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-etil-2-(1H-indazol-1-il)pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-(prop-2-inil)pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amin; N4-[(1H-benzo[d]imidazol-2-il)metil]-5-brom-2-(1H-indazol-1-il)pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-[(2-metiltiazol-4-il)metil]pirimidin-4,6-diamin; 5-brom-N4-(tetrahidro-2H-piran-4-il)-2-(1H-indazol-1-il)pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-[(1-metil-1H-pirazol-4-il)metil]pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-[(tiazol-5-il)metil]pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-[(4-metiltiazol-5-il)metil]pirimidin-4,6-diamin; 5-brom-2-(1H-indazol-1-il)-N4-(2-metoksietil)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-pirazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-(2-metoksietil)-2-(1H-pirazol-1-il)pirimidin-4,6-diamin; N4-[(1H-benzo[d]imidazol-2-il)metil]-5-brom-2-(1H-pirazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-[4-(piridin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-2-(4-(piridin-4-il)-1H-pirazol-1-il)-N4-[(tiazol-5-il)metil]pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(4-(piridin-2-il)-1H-pirazol-1-il)pirimidin-4,6-diamin; 5-brom-2-[4-(piridin-2-il)-1H-pirazol-1-il]-N4-[(tiazol-5-il)metil]pirimidin-4,6-diamin; 5-brom-N4-(2-metoksietil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-[4-(kinolin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(tetrahidro-2H-piran-4-il)-2-[4-(kinolin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-[(2-metiltiazol-4-il)metil]-2-[4-(kinolin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-[4-(kinolin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-etil-2-(4-fenil-1H-pirazol-1-il)pirimidin-4,6-diamin; 5-brom-2-[4-(4-klorfenil)-1H-pirazol-1-il]-N4-etilpirimidin-4,6-diamin; 5-brom-2-[4-(4-klorfenil)-1H-pirazol-1-il]-N4-(prop-2-inil)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-[4-(pirazin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-[4-(pirazin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-(1H-pirazolo[3,4-b]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-pirazolo[3,4-b]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-(1H-pirazolo[3,4-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-pirazolo[3,4-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-2-(1H-pirazolo[3,4-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-2-(1H-pirazolo[3,4-c]piridin-1-il)-N4-[(tiazol-5-il)metil]pirimidin-4,6-diamin; 5-brom-N4-(2-metoksietil)-2-(1H-pirazolo[3,4-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-(1H-pirazolo[4,3-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-pirazolo[4,3-c]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-(1H-pirazolo[4,3-b]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-pirazolo[4,3-b]piridin-1-il)pirimidin-4,6-diamin; 5-brom-N4-(prop-2-inil)-2-(1H-1,2,4-triazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(4-metiltiazol-5-il)metil]-2-(1H-1,2,4-triazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-(2-metoksietil)-2-(1H-1,2,4-triazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-[(tiazol-5-il)metil]-2-(1H-1,2,4-triazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-2-(1H-1,2,4-triazol-1-il)pirimidin-4,6-diamin; 1-[4-amino-5-brom-6-(prop-2-inilamino)pirimidin-2-il]-1H-pirazol-4-karboksilna kiselina; 1-[4-amino-5-brom-6-(etilamino)pirimidin-2-il]-1H-pirazol-4-karboksilna kiselina; 1-{4-[(4-metiltiazol-5-il)metilamino]-6-amino-5-brompirimidin-2-il}-1H-pirazol-4-karboksilna kiselina; {1-[4-amino-5-brom-6-(etilamino)pirimidin-2-il]-1H-pirazol-4-il}(morfolino)metanon; 5-brom-6-(1H-pirazol-1-il)-2-[4-(piridin-4-il)-1H-pirazol-1-il]pirimidin-4-amin; 5-brom-6-(1H-pirazol-1-il)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4-amin; 5-brom-2-[4-(pirazin-2-il)-1H-pirazol-1-il)-6-(1H-pirazol-1-il]pirimidin-4-amin; 5-brom-6-(1H-pirazol-1-il)-2-(1H-1,2,4-triazol-1-il)pirimidin-4-amin; 1-[4-(2-metoksietilamino)-6-amino-5-brompirimidin-2-il]-1H-pirazol-4-karboksilna kiselina; 1-[4-amino-5-brom-6-(ciklopropilmetilamino)pirimidin-2-il]-1H-pirazol-4-karboksilna kiselina; 1-[4-amino-5-brom-6-(isopropilamino)pirimidin-2-il]-1H-pirazol-4-karboksilna kiselina; 5-brom-N4-etil-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-etil-2-[4-(pirimidin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-etil-2-[4-(kinolin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-klor-N4-etil-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-klor-N4-etil-2-(1H-indazol-1-il)pirimidin-4,6-diamin; 5-klor-N4-etil-2-(5-fluor-1H-indazol-1-il)pirimidin-4,6-diamin; 5-brom-N4-etil-2-(1H-indazol-1-il)-N6-(prop-2-inil)pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-2-(1H-indazol-1-il)-N6-(prop-2-inil)pirimidin-4,6-diamin; 5-brom-N4-(tetrahidro-2H-piran-4-il)-2-(1H-indazol-1-il)-N6-(prop-2-inil)pirimidin-4,6-diamin; N4-[(1H-benzo[d]imidazol-2-il)metil]-5-brom-2-(1H-indazol-1-il)-N6-(prop-2-inil)pirimidin-4,6-diamin; 5-brom-N4-etil-N6-(prop-2-inil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-N6-(prop-2-inil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(tetrahidro-2H-piran-4-il)-N6-(prop-2-inil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; N4-[(1H-benzo[d]imidazol-2-il)metil]-5-brom-N6-(prop-2-inil)-2-[4-(piridin-2-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-etil-N6-(prop-2-inil)-2-[4-(pirimidin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-(ciklopropilmetil)-N6-etil-2-[4-(pirimidin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; 5-brom-N4-etil-N6-(tetrahidro-2H-piran-4-il)-2-[4-(pirimidin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin; i N4-[(1H-benzo[d]imidazol-2-il)metil]-5-brom-N6-etil-2-[4-(pirimidin-4-il)-1H-pirazol-1-il]pirimidin-4,6-diamin.
20. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, zajedno s farmaceutski prihvatljivom pomoćnom tvari.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkom stanju podložnom poboljšanju inhibiranju fosfodiesteraze 10, gdje se bolest ili patološko stanje podložno poboljšanju inhibiranju fosfodiesteraze 10 bira iz skupine koju čine bolesti i patološka stanja središnjeg živčanog sustava, poput shizofrenije, Huntingtonove bolesti, Parkinsonove bolesti, Alzheimerove bolesti i depresije, te respiratorni poremećaji, poput plućne hipertenzije, astme i COPD-a.
22. Kombinacijski produkt, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, te najmanje još jedan lijek, gdje se navedeni lijek bira između lijekova korisni u liječenju bolesti središnjeg živčanog sustava, poput shizofrenije, Parkinsonove bolesti, Huntingtonove bolesti, Alzheimerove bolesti i depresije, te respiratornih poremećaja, poput plućne hipertenzije, astme i COPD-a.
HRP20161495TT 2013-01-24 2016-11-11 Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) HRP20161495T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201330082A ES2480341B1 (es) 2013-01-24 2013-01-24 Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
EP14703553.9A EP2948443B1 (en) 2013-01-24 2014-01-23 New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)
PCT/EP2014/051290 WO2014114695A1 (en) 2013-01-24 2014-01-23 New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)

Publications (1)

Publication Number Publication Date
HRP20161495T1 true HRP20161495T1 (hr) 2016-12-16

Family

ID=50071592

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161495TT HRP20161495T1 (hr) 2013-01-24 2016-11-11 Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10)

Country Status (23)

Country Link
US (1) US9447095B2 (hr)
EP (1) EP2948443B1 (hr)
JP (1) JP6254194B2 (hr)
KR (1) KR101869144B1 (hr)
CN (1) CN105008346B (hr)
AU (1) AU2014209950B2 (hr)
BR (1) BR112015017678B1 (hr)
CA (1) CA2897260C (hr)
CY (1) CY1118552T1 (hr)
DK (1) DK2948443T3 (hr)
EA (1) EA026330B1 (hr)
ES (2) ES2480341B1 (hr)
HR (1) HRP20161495T1 (hr)
HU (1) HUE031831T2 (hr)
LT (1) LT2948443T (hr)
ME (1) ME02551B (hr)
MX (1) MX361160B (hr)
PL (1) PL2948443T3 (hr)
PT (1) PT2948443T (hr)
RS (1) RS55449B1 (hr)
SI (1) SI2948443T1 (hr)
SM (1) SMT201600428B (hr)
WO (1) WO2014114695A1 (hr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221103A1 (en) 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
RU2531274C2 (ru) 2009-05-07 2014-10-20 Энвиво Фармасьютикалз, Инк. Феноксиметильные гетероциклические соединения
WO2010138430A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
JP6007102B2 (ja) 2009-06-24 2016-10-12 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 画像情報に基づいた構造の輪郭の決定
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8343970B2 (en) 2010-03-12 2013-01-01 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2011119518A1 (en) * 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
WO2013052395A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors

Also Published As

Publication number Publication date
ME02551B (me) 2017-02-20
JP6254194B2 (ja) 2017-12-27
AU2014209950A1 (en) 2015-08-27
DK2948443T3 (en) 2016-12-12
ES2480341B1 (es) 2015-01-22
CN105008346A (zh) 2015-10-28
EP2948443B1 (en) 2016-08-31
MX2015009627A (es) 2016-04-25
CA2897260A1 (en) 2014-07-31
US9447095B2 (en) 2016-09-20
EA201591369A1 (ru) 2016-01-29
KR20150126601A (ko) 2015-11-12
BR112015017678A2 (pt) 2017-07-11
BR112015017678B1 (pt) 2023-02-14
JP2016505059A (ja) 2016-02-18
AU2014209950B2 (en) 2017-04-20
LT2948443T (lt) 2016-12-12
CY1118552T1 (el) 2017-07-12
ES2611170T3 (es) 2017-05-05
SMT201600428B (it) 2017-01-10
ES2480341A1 (es) 2014-07-25
MX361160B (es) 2018-11-28
KR101869144B1 (ko) 2018-07-19
CN105008346B (zh) 2018-11-13
RS55449B1 (sr) 2017-04-28
EP2948443A1 (en) 2015-12-02
HUE031831T2 (en) 2017-08-28
US20150336953A1 (en) 2015-11-26
PT2948443T (pt) 2016-11-15
SI2948443T1 (sl) 2016-12-30
EA026330B1 (ru) 2017-03-31
CA2897260C (en) 2018-11-20
PL2948443T3 (pl) 2017-02-28
WO2014114695A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
JP6298115B2 (ja) Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体
US9365562B2 (en) 1,3 substituted azetidine PDE10 inhibitors
AU2012299080B2 (en) Pyrimidine PDE10 inhibitors
JP6328145B2 (ja) Ｆｌａｐ調節因子
US9200001B2 (en) Triazolyl PDE10 inhibitors
JP2014528446A5 (hr)
US8785467B2 (en) Alkoxy pyrimidine PDE10 inhibitors
US9580413B2 (en) Substituted pyrrolidines as ROS tyrosine kinase inhibitors
EP2629616A2 (en) Substituted amino-triazolyl pde10 inhibitors
HRP20161495T1 (hr) Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10)
JP2016505059A5 (hr)
WO2016080361A1 (ja) 経口投与用医薬組成物